Ganoderma lucidum oligopeptide with anti-tumor effect and preparation method thereof
By developing Ganoderma lucidum oligopeptide EGREHVG with anti-tumor effects, the problem of unsatisfactory treatment effect of colon cancer was solved, and effective killing of colon cancer cells was achieved, which improved the treatment effect and reduced adverse reactions.
Patent Information
- Application Number
- CN202411411585.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-10
- Publication Date
- 2024-11-29
AI Technical Summary
The cure rate of colon cancer has improved, but the treatment effect is not ideal, and serious adverse reactions have reduced the patient's quality of life.
A Ganoderma lucidum oligomeric peptide with anti-tumor efficacy was developed, with an amino acid sequence of EGREHVG, prepared by recombinant expression and chemical synthesis, and used for the treatment of colon cancer.
Ganoderma lucidum oligomeric peptide EGREHVG has good killing effects on human HCT116 cells, can effectively prevent and treat colon cancer, and has broad application prospects.
Smart Images

Figure CN119039389A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a ganoderma lucidum oligopeptide with anti-tumor efficacy and a preparation method thereof. Background Art
[0002] As a traditional precious Chinese herbal medicine, Ganoderma lucidum has long been included in the "Pharmacopoeia of the People's Republic of China" and the "American Herbal Pharmacopoeia and Therapeutic Compendium". It has anti-hypertension, immunomodulatory, anti-tumor, antiviral, liver protection and other effects. As a traditional precious medicinal edible fungus in my country, Ganoderma lucidum is an important source of innovative natural medicines. At present, more than 160 compounds have been isolated from Ganoderma lucidum. Although the protein content in Ganoderma lucidum is as high as 7.52-32.05%, which is much higher than polysaccharides (0.53-3.05%) and triterpenoids (0.47-1.47%), its attention is far less than that of polysaccharides and triterpenoids. As an important carrier unit of physiological function, it is necessary to study its active ingredients. Oligopeptides are small molecule protein compounds composed of 2-10 amino acids, which have the advantages of good tissue permeability and weak immunogenicity, and have great development potential.
[0003] Colon cancer is a common malignant tumor of the lower digestive tract. Globally, the incidence of colon cancer ranks third among malignant tumors and the mortality ranks fourth. Studies have shown that overnutrition and obesity caused by uncontrolled diet are important factors in inducing colon cancer. With the changes in lifestyle and living conditions, the number of people with colon cancer will further increase. At present, the treatment of colon cancer is mainly surgical resection combined with postoperative intervention of chemotherapy, radiotherapy, and immunotherapy. With the application of new anti-colon cancer drugs, the cure rate of colon cancer has improved, but the treatment effect is not ideal, and serious adverse reactions have greatly reduced the quality of life of patients. Therefore, it is necessary to develop active drugs with better efficacy for the treatment of colon cancer.
[0004] It has been reported in the prior art that Ganoderma lucidum active substances can be used to treat colon cancer. This study is dedicated to developing a Ganoderma lucidum oligopeptide that can treat colon cancer. Summary of the invention
[0005] In view of the above-mentioned defects of the prior art, the technical problem to be solved by the present invention is that the cure rate of colon cancer is improved, but the treatment effect is not ideal, and the serious adverse reactions greatly reduce the quality of life of patients.
[0006] To achieve the above object, the present invention provides a Ganoderma lucidum oligopeptide with anti-tumor efficacy, wherein the amino acid sequence of the oligopeptide is EGREHVG.
[0007] Preferably, the polypeptide is a variant of EGREHVG obtained by substitution, addition or deletion of one amino acid, and the variant still has anti-tumor efficacy.
[0008] Preferably, the tumor is colon cancer.
[0009] Preferably, the polypeptide is prepared by recombinant expression and chemical synthesis.
[0010] In a preferred embodiment of the present invention, the present invention provides a polynucleotide that can encode the Ganoderma lucidum oligopeptide.
[0011] In another preferred embodiment of the present invention, the present invention provides an expression vector comprising a polynucleotide encoding a Ganoderma lucidum oligopeptide.
[0012] In another preferred embodiment of the present invention, the present invention provides a cell comprising a polynucleotide or an expression vector encoding a Ganoderma lucidum oligopeptide.
[0013] In another preferred embodiment of the present invention, the present invention provides a pharmaceutical composition comprising the Ganoderma lucidum oligopeptide.
[0014] In a preferred embodiment of the present invention, the Ganoderma lucidum oligopeptide is used in the preparation of anti-tumor drugs.
[0015] Preferably, the tumor is colon cancer.
[0016] The present invention uses Ganoderma lucidum as the natural source of innovative drugs, and separates the heptapeptide EGREHVG with inhibitory activity against colorectal cancer. The polypeptide has good killing effect on human HCT116 cells, can effectively prevent and treat colon cancer, and has broad application prospects.
[0017] The concept, specific structure and technical effects of the present invention will be further described below in conjunction with the accompanying drawings to fully understand the purpose, characteristics and effects of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 It is the elution curve diagram on the gel column after enzymatic hydrolysis;
[0019] Figure 2 This is the result diagram of the killing activity of each component after Sephadex G-25 chromatography on human colon cancer HCT116 cells;
[0020] Figure 3 is the ultra-high performance liquid chromatography separation spectrum of the chromatography component P2;
[0021] Figure 4 This is the secondary mass spectrum of Ganoderma lucidum oligopeptide;
[0022] Figure 5 This is a graph showing the killing activity of different concentrations of Ganoderma lucidum oligopeptides on human colon cancer HCT116 cells. DETAILED DESCRIPTION
[0023] The following describes several preferred embodiments of the present invention with reference to the drawings in the specification, so that the technical content is clearer and easier to understand. The present invention can be embodied in many different forms of embodiments, and the protection scope of the present invention is not limited to the embodiments mentioned in the text.
[0024] Example 1
[0025] The commercially available Ganoderma lucidum strain CI CC was inoculated into a seed culture medium with glucose as a carbon source, peptone and yeast extract as nitrogen sources, dipotassium hydrogen phosphate and potassium dihydrogen phosphate as buffers, and magnesium, iron and copper as mineral elements, and fermented in a shake flask at 25°C and a rotation speed of 200 r / min for 4 days to obtain a Ganoderma lucidum activated seed liquid; then the activated seed liquid was prepared into an inoculum liquid with a bacterial cell concentration of 2.0 g / L, and inoculated into a Ganoderma lucidum strain fermentation medium (soluble starch 38 g / L, ammonium chloride 5 g / L, dipotassium hydrogen phosphate 1.5 g / L, potassium dihydrogen phosphate 2 g / L, vitamin B11 g / L) at a volume ratio of 15%, and fermented in a shake flask at a temperature of 25°C and a rotation speed of 150 r / min for 8 days to obtain a Ganoderma lucidum fermentation culture liquid.
[0026] The fermented mycelium was obtained by filtering with gauze, washed with distilled water for 3 times, dried with filter paper, transferred to a mortar, poured with 2 volumes of liquid nitrogen, and ground into powder; the Ganoderma lucidum powder was added to a homogenization buffer (1% enzyme inhibitor Roche), homogenized for 30 minutes, and then centrifuged to obtain the supernatant to obtain a crude Ganoderma lucidum extract.
[0027] α-amylase (2000U / crude Ganoderma lucidum extract) was further added to the crude Ganoderma lucidum extract, and enzymolysis was performed at 40°C for 35 minutes to remove the polysaccharide attached to the protein. After enzymolysis, the enzymolysis solution was ultrafiltered through 10kDa and 3kDa ultrafiltration membranes in sequence, and the filtrate with a molecular weight less than 3kDa was collected and further separated and purified using a Sephadex G-25 gel column to obtain P1, P2, P3 and P4. The sample volume was 250mL, and the solution was eluted with distilled water at a flow rate of 2mL / min, and 5mL was collected in each tube; Figure 1 As described above, P1 is obtained by merging tubes 5-13, P2 is obtained by merging tubes 19-21, P3 is obtained by merging tubes 25-33, and P4 is obtained by merging tubes 37-47.
[0028] Human colon cancer HCT116 cells were cultured in high-glucose DMEM containing 10% FBS and 1% penicillin / streptomycin in a cell culture incubator at saturated humidity, 5% CO2 and 37°C. When the cells grew to about 85% confluence, they were digested with trypsin and passaged at a ratio of 3:1.
[0029] The components of P1-P4 that have killing activity against HCT116 cells were screened, and HCT116 cells were divided into the following experimental groups: control group, P1 group, P2 group, P3 group and P4 group. The cells were cultured for 24 hours, and the cell activity of each experimental group was detected using CCK. 10 μL CCK-8 was added to each well and cultured in a 37°C CO2 incubator for 2 hours. The OD value at 450 nm was measured on an ELISA reader.
[0030] like Figure 2 As shown, the polypeptide components of groups P1, P3 and P4 had no significant effect on inhibiting the activity of HCT116 cells, but group P2 had a significant killing effect on HCT116 cells, which has the potential to treat colon cancer.
[0031] Example 2
[0032] RP-HPLC was used to further separate and purify the P2 component. The chromatographic column used was a C18 column. The separation conditions of RP-HPLC were: isocratic elution, mobile phase A was deionized water containing 0.05% TFA; mobile phase B was acetonitrile containing 0.05% TFA. The flow rate was 1 mL / min, the injection volume was 10 μL, the sample concentration was 10 mg / mL, the column temperature was 20°C, and the elution peak was detected at 214 nm.
[0033] The RP-HPLC separation spectrum of the chromatographic component P2 is shown in Figure 3 ,like Figure 3 , 6 absorption peaks were collected during the elution process, which were recorded as F1, F2, F3, F4, and F5 respectively, and each component was freeze-dried and stored.
[0034] The amino acid sequence of component F2 was analyzed by electrospray quadrupole time-of-flight mass spectrometry, and a polypeptide with inhibitory activity against colon cancer was identified, whose amino acid sequence was EGREHVG, Figure 4 Its secondary mass spectrum.
[0035] Example 3
[0036] Natural EGREHVG is difficult to obtain. In order to reduce production costs, EGREHVG was prepared by organic solid phase synthesis, and HCT116 cells were constructed into the following experimental groups: control group, low-concentration short peptide, medium-concentration short peptide and high-concentration short peptide. The concentration of low-concentration short peptide was 0.02 mg / mL, the concentration of medium-concentration short peptide was 0.05 mg / mL, and the concentration of high-concentration short peptide was 0.1 mg / mL.
[0037] After culturing for 24 hours, CCK-8 was used to detect the cell activity of each experimental group. 10 μL CCK-8 was added to each well and cultured in a 37°C CO2 incubator for 2 hours. The OD value at 450 nm was measured on an ELISA reader.
[0038] like Figure 5 As shown, compared with the blank control group, the addition of low, medium and high concentrations of Ganoderma lucidum oligopeptides had a significant inhibitory effect on the cell activity of human HCT116 cells, and as the concentration of Ganoderma lucidum oligopeptides increased, its killing ability on human HCT116 cells also increased significantly.
[0039] The preferred specific embodiments of the present invention are described in detail above. It should be understood that ordinary technicians in the field can make many modifications and changes based on the concept of the present invention without creative work. Therefore, all technical solutions that can be obtained by technicians in the technical field based on the concept of the present invention through logical analysis, reasoning or limited experiments on the basis of the prior art should be within the scope of protection determined by the claims.
Claims
1. A Ganoderma lucidum oligopeptide with anti-tumor effect, It is characterized in that The amino acid sequence of the oligopeptide is EGREHVG.
2. The polypeptide according to claim 1, It is characterized in that The polypeptide is a variant of EGREHVG obtained by substitution, addition or deletion of one amino acid, and the variant still has anti-tumor efficacy.
3. The Ganoderma lucidum oligopeptide according to claim 1 or 2, It is characterized in that The tumor is colon cancer.
4. The Ganoderma lucidum oligopeptide according to claim 1 or 2, It is characterized in that The polypeptides are prepared by recombinant expression and chemical synthesis.
5. A polynucleotide, It is characterized in that It encodes the Ganoderma lucidum oligopeptide described in any one of claims 1-4.
6. An expression vector, It is characterized in that It comprises the polynucleotide according to claim 5.
7. A cell, It is characterized in that It comprises the polynucleotide according to claim 5 or the expression vector according to claim 6.
8. A pharmaceutical composition, It is characterized in that It comprises the Ganoderma lucidum oligopeptide described in any one of claims 1-4.
9. Use of the Ganoderma lucidum oligopeptide according to claims 1-4 and / or the pharmaceutical composition according to claim 8 in the preparation of anti-tumor drugs.
10. The use according to claim 9, It is characterized in that The tumor is colon cancer.
Citation Information
Cited By
Oligopeptide for treating colorectal polyp and preparation method thereof
CN120484057A
Ganoderma lucidum polypeptide as well as preparation method and application thereof
CN121362813A
Ganoderma lucidum oligopeptide with anti-tumor effect and preparation method thereof
CN122127414A
